Jiuyuan Gene Calls 18 Sep 2026 EGM to Vote on Proceeds Re-allocation and Articles Amendment

Bulletin Express
Yesterday

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) has convened an Extraordinary General Meeting (EGM) for 18 September 2026 at 14:30 (Beijing time) in Conference Room 3, No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou, Zhejiang Province, PRC.

The board is seeking shareholder approval for two key resolutions:

1. Ordinary Resolution – Proposed Changes in Use of Proceeds • Management will present a revised allocation plan for funds previously raised. Details of the re-allocation are contained in the circular dated 31 August 2026.

2. Special Resolution – Proposed Amendments to the Articles of Association • Shareholders will vote on updates to the Company’s governing documents, also detailed in the 31 August circular.

Voting Arrangements • All resolutions will be decided by poll, and results will be posted on the websites of the Hong Kong Stock Exchange and the Company. • The H-share register will be closed from 15 September to 18 September 2026 (both days inclusive). Holders of H-shares must lodge transfer documents by 16:30 on 14 September 2026 to qualify for attendance and voting rights. • Shareholders may appoint one or more proxies; each share carries one vote.

Logistics • The EGM is expected to last no more than half a day; attendees will bear their own travel and accommodation costs. • Identification is required for entry; corporate shareholders must provide board resolutions authorising their representatives.

Board Composition As of 31 August 2026, the board comprises: – Executive Directors: Fu Hang (Chairman & General Manager), Zhou Wei – Non-executive Directors: Wu Shihang, Albert Esteve Cruella, Fei Junjie, Yan Weiting – Independent Non-executive Directors: Zhou Zhihui, Ho Mei Yi, Dr. Zhou Demin, Dr. Huang Wenli – Employee Representative Director: Xu Feihu

Contact Information Address: No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou, Zhejiang Province, PRC, 310018 Investor Relations Contact: Mr. Hu Rong | Email: hurong@china-gene.com

Shareholders are encouraged to review the detailed circular issued on 31 August 2026 ahead of the meeting to inform their voting decisions on the proposed re-allocation of funds and amendments to the Articles of Association.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10